CCR1 inhibitor 19e
CAS No. 1220026-26-5
CCR1 inhibitor 19e( —— )
Catalog No. M10832 CAS No. 1220026-26-5
CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 258 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 392 | In Stock |
|
| 25MG | 720 | In Stock |
|
| 50MG | 1014 | In Stock |
|
| 100MG | 1479 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCCR1 inhibitor 19e
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM.
-
DescriptionCCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.
-
In VitroCCR1 antagonist 9 (Compound 19e) blocks the CCR1 chemotaxis of THP-1 cells with an IC50 of 28 nM. CCR1 antagonist 9 also blocks hERG with an IC50 of 30 μM.
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1220026-26-5
-
Formula Weight425.438
-
Molecular FormulaC20H16FN5O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (195.87 mM)
-
SMILESCS(=O)(=O)C1=NC=CC(=C1)CNC(=O)C2=CN=CC3=C2C=NN3C4=CC=C(C=C4)F
-
Chemical Name1-(4-fluorophenyl)-N-((2-(methylsulfonyl)pyridin-4-yl)methyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Harcken C, et al. Bioorg Med Chem Lett. 2018 Dec 13. pii: S0960-894X(18)30958-2. doi: 10.1016/j.bmcl.2018.12.024.
molnova catalog
related products
-
MK-0812 succinate
A potent CCR2 specific antagonist that blocks MCP-1 mediated response with an IC50 of 3.2 nM.
-
ST 016907
A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo.
-
TAK-220
A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM.
Cart
sales@molnova.com